Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

RaKa82 Jan. 29 at 2:52 PM

$IMNN do we expect any meaningful news at earnings?

1 · Reply

steplondon Jan. 27 at 7:46 AM

$IMNN have you even listened to her interview?

3 · Reply

ConcernedCitizen23 Jan. 26 at 10:27 PM

$IMNN Stacy doesnt matter. I doubt she’s the real deal maker. The chairman and the CFO are likely doing things.

1 · Reply

LKDOG Jan. 26 at 10:03 PM

$IMNN May have just been hopeful….

0 · Reply

LKDOG Jan. 26 at 9:56 PM

$IMNN Check LinkedIn ! Stacy out. ? !

1 · Reply

ConcernedCitizen23 Jan. 23 at 1:49 PM

$IMNN I see a $4.99 ask…probably fake due to low volume but nice to see

1 · Reply

whjo Jan. 22 at 6:39 PM

$IMNN buy and hold

1 · Reply

ConcernedCitizen23 Jan. 22 at 5:55 PM

$IMNN the only reason this stock isn’t $200/share is the passive lazy leadership. It’s ok though because somebody will buy them and take them out of their misery. I’m in this for the long term.

0 · Reply

RaKa82 Jan. 22 at 4:17 PM

$IMNN The company is convinced that the Ph3 data will replicate the Ph2 results. That is why they only did a small financing, just enough to get them to some interim data and do a bigger raise at higher prices or partner at that time. They did not want to dilute at these lower prices because they know what they have - a derisked Ph3 asset that will establish standard of care in ovarian cancer.

0 · Reply

LKDOG Jan. 20 at 9:27 PM

$IMNN LETS GO !!!! Get er done !!!

0 · Reply

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

Dec 29, 2025, 11:10 AM EST - 4 weeks ago

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Nov 13, 2025, 5:31 PM EST - 2 months ago

Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:45 AM EST - 2 months ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 5:11 PM EST - 2 months ago

Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript

Nov 10, 2025, 1:30 PM EST - 2 months ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Nov 10, 2025, 7:30 AM EST - 2 months ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Nov 7, 2025, 8:05 AM EST - 2 months ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Nov 6, 2025, 8:05 AM EST - 3 months ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

Nov 4, 2025, 8:05 AM EST - 3 months ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 30, 2025, 8:00 AM EDT - 3 months ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Oct 23, 2025, 10:01 AM EDT - 3 months ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Oct 20, 2025, 8:05 AM EDT - 3 months ago

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

Oct 17, 2025, 8:10 AM EDT - 3 months ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

Oct 14, 2025, 8:20 AM EDT - 3 months ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Sep 22, 2025, 8:05 AM EDT - 4 months ago

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

Sep 19, 2025, 8:05 AM EDT - 4 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

Aug 28, 2025, 8:05 AM EDT - 5 months ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 6 months ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 6 months ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 6 months ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 6 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 6 months ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 6 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 6 months ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 7 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 8 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 8 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 8 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 8 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 8 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 9 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 9 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 9 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 9 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 9 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 9 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 9 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 11 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 1 year ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 1 year ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 1 year ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 1 year ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 1 year ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 1 year ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

RaKa82 Jan. 29 at 2:52 PM

$IMNN do we expect any meaningful news at earnings?

1 · Reply

steplondon Jan. 27 at 7:46 AM

$IMNN have you even listened to her interview?

3 · Reply

ConcernedCitizen23 Jan. 26 at 10:27 PM

$IMNN Stacy doesnt matter. I doubt she’s the real deal maker. The chairman and the CFO are likely doing things.

1 · Reply

LKDOG Jan. 26 at 10:03 PM

$IMNN May have just been hopeful….

0 · Reply

LKDOG Jan. 26 at 9:56 PM

$IMNN Check LinkedIn ! Stacy out. ? !

1 · Reply

ConcernedCitizen23 Jan. 23 at 1:49 PM

$IMNN I see a $4.99 ask…probably fake due to low volume but nice to see

1 · Reply

whjo Jan. 22 at 6:39 PM

$IMNN buy and hold

1 · Reply

ConcernedCitizen23 Jan. 22 at 5:55 PM

$IMNN the only reason this stock isn’t $200/share is the passive lazy leadership. It’s ok though because somebody will buy them and take them out of their misery. I’m in this for the long term.

0 · Reply

RaKa82 Jan. 22 at 4:17 PM

0 · Reply

LKDOG Jan. 20 at 9:27 PM

$IMNN LETS GO !!!! Get er done !!!

0 · Reply

RaKa82 Jan. 20 at 6:44 PM

$IMNN C”mon Stacy, let’s get a deal done.

0 · Reply

LKDOG Jan. 17 at 3:21 PM

$IMNN Next week should be interesting. Got in waaaay too early. All we really know at this point ,is that $3 ish is the floor.

0 · Reply

ConcernedCitizen23 Jan. 16 at 8:28 PM

$IMNN it’s not gonna do anything until it does everything. When? Wtf knows

1 · Reply

Jacks10 Jan. 16 at 3:35 PM

$IMNN The current share price on this is ridiculous! Time to move it up!

1 · Reply

bomber1 Jan. 16 at 12:22 PM

$IMNN One announcement a month, to give the impression that in the end no progress is being made; in fact, it continues to go backwards!!! How long can it last? At this rate, it's likely that the stock will return to one dollar; and then? The film again, already seen, and the delisting; and then the plan to avoid being delisted from the Nasdaq...etc etc.!! But how many years do these people want to work this way? Do they get by on handouts? I don't know: it's embarrassing, even for those who work there!! For these scientific researchers...

1 · Reply

jjegglie Jan. 16 at 9:31 AM

$IMNN ah, yes, the mystery partner fails to show yet again. Who could have guessed this?

0 · Reply

jjegglie Jan. 15 at 9:55 PM

$IMNN Things going well here 🤣🤣. This has a long way to go down following the 70% dilution though

0 · Reply

ConcernedCitizen23 Jan. 15 at 2:03 PM

$IMNN hey there we’re up to 5 clinical sites for phase 3! Check out clinical http://trials.gov yourself to verify! Let’s go guys!

1 · Reply

LKDOG Jan. 15 at 1:23 PM

$IMNN

1 · Reply

ConcernedCitizen23 Jan. 14 at 2:19 PM

$IMNN the current ceo is not a great salesperson. It’s ok though because the chairman and the new CFO should be able to get any deals done around her. She can continue crunching phase 3 data while they sell the company.

2 · Reply

LKDOG Jan. 14 at 1:12 PM

$IMNN I would hope the DNA inoculations would be additive to the overall value of IMNN

0 · Reply

ConcernedCitizen23 Jan. 13 at 7:47 PM

$IMNN it’s possible no deal at JP Morgan conference but if there is….$200/share incoming fast

2 · Reply

Market Cap	10.44M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	25,300
Avg Vol	50,962
Day's Range	N/A - N/A
Shares Out	3.07M
Stochastic %K	5%
Beta	1.94
Analysts	Strong Sell
Price Target	$24.33